Description:
Diabetes mellitus (DM) is a chronic metabolic disorder disease. DM presents in two main types 1 and 2. Type 2 DM was caused by genetic and lifestyle which was the biggest contributor to DM cases. Many patients with type 2 DM treated with combination therapy using Fix Dose Combination (FDC) preparation to increase patients compliance and therapeutic effect. FDC preparations contained metformin and glimepiride. Assay of these combination was not found in compendial. A rapid, simple, specific method analysis of metformin and glimepiride has been developed in this riset using TLC-spectrofluorometry. Metformin and glimepiride content in tablet were determined by the TLCspectrofluorometry using dansyl chloride as derivatization agent under alkali conditions. In the TLC method, metformin and glimepiride were dissolved with methanol and gives Rf values of 0.52 and 0.70, respectively in system containing silika gel GF254 as stationary base and methanol:water: glacial asetic acid (6:4:0.25) as developing solvent. TLC results were scraped off and reacted using dansyl chloride 0.1% then fluorescence intensity measurements were carried out at emission wavelength 483 nm for metformin and 489 nm for glimepiride. Method validation is done by determining linearity, accuracy, precision, Limit Of Detection (LOD) and Limit Of Quantization (LOQ).

URL:
http://103.158.96.210:88/web_repository/uploads/33708-191727-2-PB.pdf

Type:
Journal

Document:
Diploma III Farmasi

Date:
23-06-2024

Author:
SALSABILA ADLINA